Citations (171)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
Osama Alshari, Yazan O Al Zu’bi, Ahmed H Al Sharie, Farouk H Wafai, Abdelwahab J Aleshawi, Farah H Atawneh, Hasan A Obeidat, Majd N Daoud, Mohammad Z Khrais, Dima Albals & Faize Tubaishat. (2021) Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor. Therapeutics and Clinical Risk Management 17, pages 963-973.
Read now
Read now
Maen Hussein, Marina Maglakelidze, Donald A Richards, Marielle Sabatini, Todd A Gersten, Keith Lerro, Ivan Sinielnikov, Alexander Spira, Yili Pritchett, Joyce M Antal, Rajesh Malik & J Thaddeus Beck. (2021) Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies. Cancer Management and Research 13, pages 6207-6218.
Read now
Read now
Derek Weycker, Mark Bensink, Alexander Lonshteyn, Robin Doroff & David Chandler. (2019) Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment. Current Medical Research and Opinion 35:6, pages 1073-1080.
Read now
Read now
Alper Sevinç, Metin Özkan, Ahmet Özet, Faysal Dane, Berna Öksüzoğlu, Abdurrahman Işıkdoğan, Feyyaz Özdemir, Doğan Uncu, Mahmut Gümüş, Türkkan Evrensel, Arzu Yaren, Oğuz Kara & Salim Başol Tekin. (2018) Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia. OncoTargets and Therapy 11, pages 419-426.
Read now
Read now
Patrick Tilleul, William Jacot, Corinne Emery, Antoine Lafuma & Julie Gourmelen. (2017) Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database. Journal of Medical Economics 20:12, pages 1261-1267.
Read now
Read now
Derek Weycker, Mark Bensink, Alexander Lonshteyn, Robin Doroff & David Chandler. (2017) Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Current Medical Research and Opinion 33:12, pages 2107-2113.
Read now
Read now
Vicki A. Morrison, Edie A. Weller, Thomas M. Habermann, Shuli Li, Richard I. Fisher, Bruce D. Cheson & Bruce A. Peterson. (2017) Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). Leukemia & Lymphoma 58:8, pages 1814-1822.
Read now
Read now
Kelly Fust, Anju Parthan, Michael Maschio, Qing Gu, Xiaoyan Li, Gary H. Lyman, Spiros Tzivelekis, Guillermo Villa & Milton C. Weinstein. (2017) Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. Expert Review of Pharmacoeconomics & Outcomes Research 17:1, pages 39-52.
Read now
Read now
Philipp Wohlfarth, Alexander Carlström, Thomas Staudinger, Sabine Clauss, Alexander Hermann, Werner Rabitsch, Andja Bojic, Cathrin Skrabs, Edit Porpaczy, Ana-Iris Schiefer, Peter Valent, Paul Knöbl, Hermine Agis, Alexander Hauswirth, Ulrich Jäger, Michael Kundi, Wolfgang R. Sperr & Peter Schellongowski. (2016) Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma 57:8, pages 1831-1838.
Read now
Read now
Gary H. Lyman, Marek S. Poniewierski & Eva Culakova. (2016) Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma. Expert Opinion on Drug Safety 15:4, pages 483-492.
Read now
Read now
Gary H. Lyman, Jeffrey Crawford, Dianne Tomita, Sadie Whittaker & David C. Dale. (2016) Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma 57:2, pages 283-290.
Read now
Read now
Xiao Liu, Dao Feng Wang, Yi Fang, Wen Feng Ye, Shu Liu & Ning Lou. (2015) Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia. Leukemia & Lymphoma 56:1, pages 85-91.
Read now
Read now
Chun Chao, Roberto Rodriguez, John H. Page, Su-Jau Yang, Julie Huynh & Victoria M. Chia. (2015) History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis. Leukemia & Lymphoma 56:1, pages 72-79.
Read now
Read now
Michael Fiegl, Günther G. Steger, Michael Studnicka, Wolfgang Eisterer, Christine Jaeger & Wolfgang Willenbacher. (2013) Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study. Current Medical Research and Opinion 29:5, pages 505-515.
Read now
Read now
Scott F. Huntington, Mahsa S. Talbott, John P. Greer, David S. Morgan & Nishitha Reddy. (2012) Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Leukemia & Lymphoma 53:8, pages 1461-1468.
Read now
Read now
José Ignacio Mayordomo, Andrés López, Núria Viñolas, Javier Castellanos, Sonia Pernas, Juan Domingo Alonso, Adolfo Frau, Miquel Layola, José Antonio Gasquet & Jordi Sánchez. (2009) Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Current Medical Research and Opinion 25:10, pages 2533-2542.
Read now
Read now
Gary Lyman, Anjana Lalla, Richard Barron & Robert W. Dubois. (2009) Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Current Medical Research and Opinion 25:2, pages 401-411.
Read now
Read now
Arthur P. Rabinowitz, Neil J. Weiner, Bruce S. Tronic, Moshe Fridman, Rebecca F. Liberman & David J. Delgado. (2006) Severe neutropenia in CHOP occurs most frequently in cycle 1: A predictive model. Leukemia & Lymphoma 47:5, pages 853-858.
Read now
Read now
Gary H Lyman. (2005) Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action. Expert Opinion on Biological Therapy 5:12, pages 1635-1646.
Read now
Read now
Rami S Komrokji & Gary H Lyman. (2004) The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opinion on Biological Therapy 4:12, pages 1897-1910.
Read now
Read now
Articles from other publishers (151)
Adriana Stryczyńska-Mirocha, Stanisław Łącki-Zynzeling, Maciej Borówka, Zofia I. Niemir, Sylwia Kozak, Aleksander J. Owczarek & Jerzy Chudek. (2023) A study indicates an essential link between a mild deterioration in excretory kidney function and the risk of neutropenia during cancer chemotherapy. Supportive Care in Cancer 31:9.
Crossref
Crossref
Byeol-Eun Jeon, Ji-Eun Lee, Jungwook Park, Hyejung Jung, Eun Gyung Park, Du Hyeong Lee, Young-Su Seo, Heui-Soo Kim, Ho-Jin Shin & Sang-Woo Kim. (2023) Transcriptomic analysis of neutrophil apoptosis induced by diffuse large B-cell lymphoma unveils a potential role in neutropenia. Genes & Genomics 45:8, pages 1013-1024.
Crossref
Crossref
Mujie Li, Quan Wang, Peng Lu, Deying Zhang, Yi Hua, Feng Liu, Xing Liu, Tao Lin, Guanghui Wei & Dawei He. (2023) Development of a Machine Learning-Based Prediction Model for Chemotherapy-Induced Myelosuppression in Children with Wilms’ Tumor. Cancers 15:4, pages 1078.
Crossref
Crossref
Ilgın Akbıyık, Deniz Yüce, Ayşe Kars & Meltem Gülhan Halil. (2022) Association of frailty with chemotherapy toxicity in chemotherapy-naive older patients with cancer. Supportive Care in Cancer 30:12, pages 9975-9981.
Crossref
Crossref
Nicole M. Kuderer, Aakash Desai, Maryam B. Lustberg & Gary H. Lyman. (2022) Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nature Reviews Clinical Oncology 19:11, pages 681-697.
Crossref
Crossref
Do Young Kim, Jehyun Nam, Joo-Seop Chung, Byeol Eun Jeon, Ji Hyun Lee, Jae-Cheol Jo, Sang-Woo Kim & Ho-Jin Shin. (2022) Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma. Cancer Research and Treatment 54:4, pages 1256-1267.
Crossref
Crossref
Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh & Won Seog Kim. (2022) Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. Cancer Research and Treatment 54:4, pages 1268-1277.
Crossref
Crossref
Yoshitaka Saito, Yoh Takekuma, Naofumi Shinagawa & Mitsuru Sugawara. (2022) Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer. Supportive Care in Cancer 30:5, pages 4081-4088.
Crossref
Crossref
I. B. Kononenko, A. V. Snegovoy & V. B. Larionova. (2022) Chemotherapy limiting neutropenia. Is prevention required?. Oncohematology 17:1, pages 135-142.
Crossref
Crossref
Mehmet Bakirtas, TuğçeNur Yiğenoğlu, Semih Başci, BaharUncu Ulu, Samet Yaman, MerihKizil Çakar, MehmetSinan Dal & Fevzi Altuntaş. (2022) Febrile neutropenia risk factors in actively treated diffuse large B-cell lymphoma patients. Iraqi Journal of Hematology 11:1, pages 7.
Crossref
Crossref
M. S. Hardianti, S. A. Setiawan, M. R. Bagaskoro, N. Anggorowati, I. Purwanto, K. W. Taroeno-Hariadi, J. Kurnianda & S. H. Hutajulu. (2021) Risk Factors for Neutropenia after the First Cycle of Chemotherapy for Non-Hodgkin Lymphoma. European Journal of Medical and Health Sciences 3:6, pages 73-77.
Crossref
Crossref
Ching-Yu Wang, Coy D. Heldermon, Scott M. Vouri, Haesuk Park, Sarah E. Wheeler, Brian Hemendra Ramnaraign, Nam Hoang Dang & Joshua D. Brown. (2021) Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019. JAMA Network Open 4:11, pages e2133474.
Crossref
Crossref
Shruti Rastogi, Vivekananda Kalaiselvan, Sher Ali, Ajaz Ahmad, Sameer Ahmad Guru & Maryam Sarwat. (2021) Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis. Biology 10:10, pages 1069.
Crossref
Crossref
Aditi Mittal, Ranga R. Rangaraju, Amit Agarwal, D. Chandragouda, Sandeep Batra & Suhail Qureshi. (2021) Estimating the Risk of Chemotherapy Toxicity in Indian Geriatric Patient Population and Utility of Chemotherapy Risk Assessment Scale for High Age Patients (CRASH) Score. South Asian Journal of Cancer 10:03, pages 161-166.
Crossref
Crossref
Matthew S Painschab, Racquel Kohler, Stephen Kimani, Wilberforce Mhango, Bongani Kaimila, Takondwa Zuze, Victor Mithi, Edwards Kasonkanji, Noel Mumba, Richard Nyasosela, Stephanie Wheeler & Satish Gopal. (2021) Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis. The Lancet Global Health 9:9, pages e1305-e1313.
Crossref
Crossref
Jaekyung Cheon, Hyeon-Su Im, Ho-Jin Shin, Inho Kim, Won Sik Lee, Kyung-Hun Lee, Seong Kyu Park, Min Kyoung Kim, Un Jong Choi, Jung Han Kim, IlKyun Lee & Jae-Cheol Jo. (2021) Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea. Supportive Care in Cancer 29:9, pages 5383-5390.
Crossref
Crossref
Edward Li, Dylan J. Mezzio, David Campbell, Kim Campbell & Gary H. Lyman. (2021) Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncology Practice 17:8, pages e1235-e1245.
Crossref
Crossref
Masataka Ise, Kensuke Matsuda, Arika Shimura, Yosuke Masamoto & Mineo Kurokawa. (2021) Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients. International Journal of Hematology 113:6, pages 823-831.
Crossref
Crossref
Annika Y. Classen, Larissa Henze, Marie von Lilienfeld-Toal, Georg Maschmeyer, Michael Sandherr, Luisa Durán Graeff, Nael Alakel, Maximilian Christopeit, Stefan W. Krause, Karin Mayer, Silke Neumann, Oliver A. Cornely, Olaf Penack, Florian Weißinger, Hans-Heinrich Wolf & Jörg Janne Vehreschild. (2021) Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Annals of Hematology 100:6, pages 1603-1620.
Crossref
Crossref
Takashi Ishikawa, Kentaro Sakamaki, Kazutaka Narui, Hideki Nishimura, Takafumi Sangai, Kentaro Tamaki, Yoshie Hasegawa, Ken-ichi Watanabe, Nobuyasu Suganuma, Shintaro Michishita, Sadatoshi Sugae, Tomohiko Aihara, Koichiro Tsugawa, Hirose Kaise, Naruto Taira & Hirofumi Mukai. (2021) Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study. The Breast 56, pages 70-77.
Crossref
Crossref
Pamala A. PawloskiCara L. McDermottJames H. Marshall, Vanita PindoliaCatherine M. LockhartCatherine A. Panozzo, Jeffrey S. Brown & Bernadette Eichelberger. (2021) BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High–Neutropenia Risk Chemotherapy. Journal of the National Comprehensive Cancer Network 19:13, pages 141-148.
Crossref
Crossref
Kana Oiwa, Kei Fujita, Shin Lee, Tetsuji Morishita, Hikaru Tsukasaki, Eiju Negoro, Takanori Ueda & Takahiro Yamauchi. (2021) Utility of the Geriatric 8 for the Prediction of Therapy-Related Toxicity in Older Adults with Diffuse Large B-Cell Lymphoma. The Oncologist 26:3, pages 215-223.
Crossref
Crossref
Elizabeth A. GulleenMawulolo K. AmekoJohn E. AinsworthLaura E. BarnesChristopher C. Moore. (2020) Predictive Models of Fever, ICU Transfer, and Mortality in Hospitalized Patients With Neutropenia. Critical Care Explorations 2:12, pages e0289.
Crossref
Crossref
I. B. Kononenko, A. V. Snegovoy, O. P. Grebennikova, V. Yu. Sel’chuk & O. V. Palchinskaia. (2020) Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy. Journal of Modern Oncology 22:3, pages 133-141.
Crossref
Crossref
Masahiro Yokoyama, Yoshiharu Kusano, Anna Nishihara, Norihito Inoue, Noriko Nishimura, Yuko Mishima, Yasuhito Terui, Tomoyuki Nukada, Takanobu Nomura & Kiyohiko Hatake. (2019) Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2). Supportive Care in Cancer 28:2, pages 571-579.
Crossref
Crossref
EntisarHadi Al-Shammary & DhuhaaJassim Mohammed. (2020) Chemotherapy-induced neutropenia after initial and subsequent chemotherapy cycle of non-hodgkin lymphoma. Mustansiriya Medical Journal 19:1, pages 16.
Crossref
Crossref
Vicki A. Morrison. 2020. Geriatric Oncology. Geriatric Oncology
583
612
.
Alberto Bongiovanni, Federica Recine, Valentina Fausti, Benedetta Rossi, Laura Mercatali, Chiara Liverani, Alessandro De Vita, Lorena Gurrieri, Silvia De Bonis, Giacomo Miserocchi, Chiara Spadazzi, Sebastiano Calpona, Nada Riva, Claudia Cocchi & Toni Ibrahim. (2019) Clinical role of filgrastim in the management of patients at risk of prolonged severe neutropenia: An evidence‐based review. International Journal of Clinical Practice 73:11.
Crossref
Crossref
Aditi Mittal, Amit Agrawal, Sandeep Batra, Chandragouda Dodagoudar & Suhail Qureshi. (2021) Chemotherapy Toxicity in Elderly Population ≥65 Years: A Tertiary Care Hospital Experience from India. Indian Journal of Medical and Paediatric Oncology 40:04, pages 531-535.
Crossref
Crossref
Hassam Baig, Barbara Somlo, Melissa Eisen, Scott Stryker, Mark Bensink & Phuong K Morrow. (2018) Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level. Journal of Oncology Pharmacy Practice 25:7, pages 1576-1585.
Crossref
Crossref
Andrew R Zullo, Uvette Lou, Sarah E Cabral, Justin Huynh & Christine M Berard-Collins. (2018) Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia. Journal of Oncology Pharmacy Practice 25:6, pages 1357-1365.
Crossref
Crossref
Pinkie Chambers, Yogini Jani, Li Wei, Emma Kipps, Martin D. Forster & Ian C. K. Wong. (2019) Patient factors and their impact on neutropenic events: a systematic review and meta-analysis. Supportive Care in Cancer 27:7, pages 2413-2424.
Crossref
Crossref
Maria La Nasa, John Gaughan & Elyce Cardonick. (2019) Incidence of Neonatal Neutropenia and Leukopenia After In Utero Exposure to Chemotherapy for Maternal Cancer. American Journal of Clinical Oncology 42:4, pages 351-354.
Crossref
Crossref
Koki Goto, Ryusei Matsuyama, Yusuke Suwa, Sayaka Arisaka, Toshiaki Kadokura, Mari Sato, Ryutaro Mori, Takafumi Kumamoto, Masataka Taguri & Itaru Endo. (2018) The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer. Cancer Chemotherapy and Pharmacology 82:6, pages 953-960.
Crossref
Crossref
Ashutosh MukherjiAshutosh Mukherji. 2018. Basics of Planning and Management of Patients during Radiation Therapy. Basics of Planning and Management of Patients during Radiation Therapy
349
355
.
Vicki A. Morrison. 2018. Geriatric Oncology. Geriatric Oncology
1
31
.
Yassine Lalami & Jean Klastersky. (2017) Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. Critical Reviews in Oncology/Hematology 120, pages 163-179.
Crossref
Crossref
Sourav Mishra, Venkatraman Radhakrishnan, Prasanth Ganesan, Rejiv Rajendranath, Swaminathan Rajaraman, Trivadi S. Ganesan & Tenali Gnana Sagar. (2017) Predictors of Chemotherapy Related Toxicities in Elderly Lymphoma Patients: Experience from a Tertiary Cancer Centre. Indian Journal of Hematology and Blood Transfusion 33:4, pages 470-476.
Crossref
Crossref
Masahiro Yokoyama, Yoshiharu Kusano, Anna Takahashi, Norihito Inoue, Kyoko Ueda, Noriko Nishimura, Yuko Mishima, Yasuhito Terui, Tomoyuki Nukada, Takanobu Nomura & Kiyohiko Hatake. (2017) Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan. Supportive Care in Cancer 25:11, pages 3313-3320.
Crossref
Crossref
Esse I. H. Akpo, Irshaad R. Jansen, Edith Maes & Steven Simoens. (2017) Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer. Frontiers in Pharmacology 8.
Crossref
Crossref
Stephen Brokx, Louise Scrocchi, Nirmesh Shah & Jason Dowd. (2017) A demonstration of analytical similarity comparing a proposed biosimilar pegfilgrastim and reference pegfilgrastim. Biologicals 48, pages 28-38.
Crossref
Crossref
Gustavo Henrique Rodrigues, Graziella Chagas Jaguar, Fabio Abreu Alves, Andre Guollo, Vanessa Oliveira Camandoni, Aline Santos Damascena & Vladmir Claudio Cordeiro Lima. (2017) Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy. Lasers in Medical Science 32:5, pages 1089-1095.
Crossref
Crossref
Claire Dendle, Michael Gilbertson, Tim Spelman, Rhonda L. Stuart, Tony M. Korman, Karin Thursky, Stephen Opat & Zoe McQuilten. (2017) Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma. Scientific Reports 7:1.
Crossref
Crossref
Tamás Pinter, Zandra Klippel, Alvydas Cesas, Adina Croitoru, Jochen Decaestecker, Peter Gibbs, Yevhen Hotko, Jacek Jassem, Galina Kurteva, Jan Novotny, Seamus O'Reilly, Tomas Salek, Maureen Reiner, Phuong Khanh Morrow, Mi Rim Choi, Sadie Whittaker & Charles Blanke. (2017) A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). Clinical Colorectal Cancer 16:2, pages 103-114.e3.
Crossref
Crossref
N.G. Zaorsky, T.M. Churilla, B.L. Egleston, S.G. Fisher, J.A. Ridge, E.M. Horwitz & J.E. Meyer. (2017) Causes of death among cancer patients. Annals of Oncology 28:2, pages 400-407.
Crossref
Crossref
Zarka Samoon, Madiha Beg, Munira Shabbir Moosajee, Mahwish Kamran, Nehal Masood, Afshan Asghar & Adeel Ahmed. (2017) Applying Multinational Association of Supportive Care of Cancer Index Score for Identifying Febrile Neutropenia Patients at High Risk of Complications at Tertiary Care Hospital, Pakistan. Open Journal of Epidemiology 07:02, pages 159-174.
Crossref
Crossref
Daiki Tsuji, Midori Ikeda, Keisuke Yamamoto, Harumi Nakamori, Yong-Il Kim, Yohei Kawasaki, Aki Otake, Mari Yokoi, Kazuyuki Inoue, Keita Hirai, Hidenori Nakamichi, Umi Tokou, Mitsuru Shiokawa & Kunihiko Itoh. (2016) Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients. Medicine 95:44, pages e5151.
Crossref
Crossref
Xiaoyan Li, Rakesh Luthra, Phuong K Morrow, Maxine D Fisher, Maureen Reiner, Richard L Barron & Wendy J Langeberg. (2016) Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle. Journal of Oncology Pharmacy Practice 22:5, pages 679-689.
Crossref
Crossref
Leila Family, Lanfang Xu, Hairong Xu, Kimberly Cannavale, Olivia Sattayapiwat, John H. Page, Chet Bohac & Chun Chao. (2016) The effect of chemotherapy-induced anemia on dose reduction and dose delay. Supportive Care in Cancer 24:10, pages 4263-4271.
Crossref
Crossref
Jordan M. Harrison, Philip J. Stella, Beth LaVasseur, Paul T. Adams, Lauren Swafford, JoAnn Lewis, Kari Mendelsohn-Victor & Christopher R. Friese. (2016) Toxicity-Related Factors Associated With Use of Services Among Community Oncology Patients. Journal of Oncology Practice 12:8, pages e818-e827.
Crossref
Crossref
Derek Weycker, Xiaoyan Li, Rich Barron, Yanli Li, Maureen Reiner, Alex Kartashov, Jacqueline Figueredo, Spiros Tzivelekis & Jacob Garcia. (2015) Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice. Supportive Care in Cancer 24:6, pages 2481-2490.
Crossref
Crossref
Gary H. Lyman. (2016) Issues on the Use of White Blood Cell Growth Factors in Oncology Practice. American Society of Clinical Oncology Educational Book:36, pages e528-e532.
Crossref
Crossref
Derek Weycker, Xiaoyan Li, Jacqueline Figueredo, Rich Barron, Spiros Tzivelekis & May Hagiwara. (2015) Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?. Supportive Care in Cancer 24:5, pages 2309-2316.
Crossref
Crossref
Sophie Nahon, Mansour Rastkhah, Meher Ben Abdelghani, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau & Jean-Luc Labourey. (2015) Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study. Supportive Care in Cancer 24:5, pages 1991-1998.
Crossref
Crossref
EISEKI USAMI, MICHIO KIMURA, MINA IWAI, SHOYA TAKENAKA, HITOMI TERAMACHI & TOMOAKI YOSHIMURA. (2016) Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting. Molecular and Clinical Oncology 4:4, pages 591-596.
Crossref
Crossref
Xiao Jun Wang, Tiffany Tang, Mohamad Farid, Richard Quek, Miriam Tao, Soon Thye Lim, Hwee Lin Wee & Alexandre Chan. (2016) Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. PLOS ONE 11:2, pages e0148901.
Crossref
Crossref
Min Ji Kwak, Srinivas R. Banala, Kalen Jacobson & Demetrios N. Kyriacou. 2016. Oncologic Emergency Medicine. Oncologic Emergency Medicine
223
233
.
Ji Hyun Park, Hyeon-Young Kim, Hanna Lee & Eun Kyoung Yun. (2015) A retrospective analysis to identify the factors affecting infection in patients undergoing chemotherapy. European Journal of Oncology Nursing 19:6, pages 597-603.
Crossref
Crossref
Thomas J. SmithKari BohlkeGary H. LymanKenneth R. CarsonJeffrey CrawfordScott J. CrossJohn M. GoldbergJames L. KhatcheressianNatasha B. LeighlCheryl L. PerkinsGeorge SomloJames L. WadeAntoinette J. WozniakJames O. Armitage. (2015) Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology 33:28, pages 3199-3212.
Crossref
Crossref
Gary H. Lyman, David C. Dale, Jason C. Legg, Esteban Abella, Phuong Khanh Morrow, Sadie Whittaker & Jeffrey Crawford. (2015) Assessing patients’ risk of febrile neutropenia: is there a correlation between physician‐assessed risk and model‐predicted risk?. Cancer Medicine 4:8, pages 1153-1160.
Crossref
Crossref
Scott E. Evans & David E. Ost. (2015) Pneumonia in the neutropenic cancer patient. Current Opinion in Pulmonary Medicine 21:3, pages 260-271.
Crossref
Crossref
Xiao Jun Wang, Shaun Eric Lopez & Alexandre Chan. (2015) Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review. Critical Reviews in Oncology/Hematology 94:2, pages 201-212.
Crossref
Crossref
D.E. Issa, H. Gelderblom, P.J. Lugtenburg, M.P. van Herk-Sukel, L.M.A. Houweling, M. De La Orden, M.E. van der Werf-Langenberg, J.W.R. Nortier & F.A. de Jong. (2015) Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database. European Journal of Cancer Care 24:2, pages 232-241.
Crossref
Crossref
Vicki A. Morrison, Paul Hamlin, Pierre Soubeyran, Reinhard Stauder, Punit Wadhwa, Matti Aapro & Stuart Lichtman. (2015) Diffuse large B-cell lymphoma in the elderly: Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper. Journal of Geriatric Oncology 6:2, pages 141-152.
Crossref
Crossref
Henry J Henk, Xiaoyan Li, Laura K Becker, Hairong Xu, Qi Gong, Robert G Deeter & Richard L Barron. (2015) Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design. Journal of Comparative Effectiveness Research 4:1, pages 37-50.
Crossref
Crossref
Xiao Jun Wang, Mabel Wong, Li Yang Hsu & Alexandre Chan. (2014) Costs associated with febrile neutropenia in solid tumor and lymphoma patients – an observational study in Singapore. BMC Health Services Research 14:1.
Crossref
Crossref
C. Chao, J.H. Page, S.-J. Yang, R. Rodriguez, J. Huynh & V.M. Chia. (2014) History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Annals of Oncology 25:9, pages 1821-1829.
Crossref
Crossref
Lee S. Schwartzberg, Mansoor Saleh, Sadie Whittaker & Esteban Abella. (2014) Severe neutropenia and relative dose intensity among patients <65 and ≥65 years with non-Hodgkin’s lymphoma receiving CHOP-based chemotherapy. Supportive Care in Cancer 22:7, pages 1833-1841.
Crossref
Crossref
Derek Weycker, Richard Barron, Alex Kartashov, Jason Legg & Gary H Lyman. (2013) Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. Journal of Oncology Pharmacy Practice 20:3, pages 190-198.
Crossref
Crossref
Gary H. Lyman, Esteban Abella & Ruth Pettengell. (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Critical Reviews in Oncology/Hematology 90:3, pages 190-199.
Crossref
Crossref
Eva Culakova, Ramya Thota, Marek S. Poniewierski, Nicole M. Kuderer, Adane F. Wogu, David C. Dale, Jeffrey Crawford & Gary H. Lyman. (2014) Patterns of chemotherapy‐associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Medicine 3:2, pages 434-444.
Crossref
Crossref
K. Krzemieniecki, P. Sevelda, F. Erdkamp, M. Smakal, M. Schwenkglenks, J. Puertas, A. Trojan, Z. Szabo, K. Bendall & J. Maenpaa. (2013) Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice. Supportive Care in Cancer 22:3, pages 667-677.
Crossref
Crossref
Hisaharu Shikata, Yoshihiro Yakushijin, Jun Yamanouchi, Taichi Azuma & Masaki Yasukawa. (2013) Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP. International Journal of Clinical Oncology 19:1, pages 178-185.
Crossref
Crossref
Ryoichi Yano. (2014) Risk Factors of Severe Neutropenia during Cancer Chemotherapy. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 40:6, pages 317-333.
Crossref
Crossref
Yong Won Choi, Seong Hyun Jeong, Mi Sun Ahn, Hyun Woo Lee, Seok Yun Kang, Jin-Hyuk Choi, U Ram Jin & Joon Seong Park. (2014) Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP. Journal of Korean Medical Science 29:11, pages 1493.
Crossref
Crossref
John Glaspy. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
532
541.e10
.
Jean A. KlasterskyJean A. Klastersky. 2014. Febrile Neutropenia. Febrile Neutropenia
13
26
.
A. Roohullah, A. Moniwa, C. Wood, M. Humble, M. Balm, J. Carter & R. Weinkove. (2013) Imipenem versus piperacillin/tazobactam for empiric treatment of neutropenic fever in adults. Internal Medicine Journal 43:10, pages 1151-1154.
Crossref
Crossref
Roopesh Kansara, Rajat Kumar & Matthew Seftel. (2013) Is primary prophylaxis with granulocyte colony stimulating factor (G-CSF) indicated in the treatment of lymphoma?. Transfusion and Apheresis Science 49:1, pages 51-55.
Crossref
Crossref
Midori Shibuya, Mari Kogo, Tatsuya Kurihara, Yusuke Shikama, Hiroaki Nakajima, Keiichiro Yoneyama & Yuji Kiuchi. (2013) Analysis of the Risk Factors for Severe Neutropenia in Advanced Non-Small Cell Lung Cancer after the First Course of Chemotherapy with Third-Generation Agents進行非小細胞肺がん患者における第3世代抗がん剤を含む初回化学療法施行後の重篤な好中球減少症発現に関与する危険因子の検討. YAKUGAKU ZASSHI 133:6, pages 703-709.
Crossref
Crossref
ZHENGXIAO OUYANG, DAN PENG & DIBYA PURUSH DHAKAL. (2013) Risk factors for hematological toxicity of chemotherapy for bone and soft tissue sarcoma. Oncology Letters 5:5, pages 1736-1740.
Crossref
Crossref
Li-Lu Chang, Susan M. Schneider, Shao-Chin Chiang & Cheng-Fang Horng. (2013) Implementing an Evidence-Based Risk Assessment Tool to Predict Chemotherapy-Induced Neutropenia in Women With Breast Cancer. Cancer Nursing 36:3, pages 198-205.
Crossref
Crossref
Victoria M. Chia, John H. Page, Roberto Rodriguez, Su-Jau Yang, Julie Huynh & Chun Chao. (2013) Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. Breast Cancer Research and Treatment 138:2, pages 621-631.
Crossref
Crossref
Sophie Lee, Angela Knox, Irene S. L. Zeng, Christin Coomarasamy, Hilary Blacklock & Samar Issa. (2012) Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost–benefit and quality of life analysis. Supportive Care in Cancer 21:3, pages 841-846.
Crossref
Crossref
Pieternella Lugtenburg, Antonio Salar Silvestre, Francesca G. Rossi, Lucien Noens, Wanda Krall, Kate Bendall, Zsolt Szabo & Ulrich Jaeger. (2012) Impact of Age Group on Febrile Neutropenia Risk Assessment and Management in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Regimens. Clinical Lymphoma Myeloma and Leukemia 12:5, pages 297-305.
Crossref
Crossref
Shannon L. Michels, Rich L. Barron, Matthew W. Reynolds, Karen Smoyer Tomic, Jingbo Yu & Gary H. Lyman. (2012) Costs Associated with Febrile Neutropenia in the US. PharmacoEconomics 30:9, pages 809-823.
Crossref
Crossref
M. Aapro, J. Rüffer & S. Fruehauf. (2012) Haematological support, fatigue and elderly patients. Journal of Geriatric Oncology 3:3, pages 246-255.
Crossref
Crossref
Martine Extermann, Ivette Boler, Richard R. Reich, Gary H. Lyman, Richard H. Brown, Joseph DeFelice, Richard M. Levine, Eric T. Lubiner, Pablo Reyes, Frederic J. SchreiberIIIIII & Lodovico Balducci. (2011) Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score. Cancer 118:13, pages 3377-3386.
Crossref
Crossref
Antonio Salar, Corinne Haioun, Francesca G. Rossi, Ulrich Duehrsen, Ruth Pettengell, Hans E. Johnsen, Ulrich Jaeger, Gregor Verhoef, Matthias Schwenkglenks, Pamela Bacon, Kate Bendall & Pieternella J. Lugtenburg. (2012) The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice. Leukemia Research 36:5, pages 548-553.
Crossref
Crossref
Kelvin K.W. ChanEric SiuMurray D. KrahnKevin ImrieShabbir M.H. Alibhai. (2012) Cost-Utility Analysis of Primary Prophylaxis Versus Secondary Prophylaxis With Granulocyte Colony-Stimulating Factor in Elderly Patients With Diffuse Aggressive Lymphoma Receiving Curative-Intent Chemotherapy. Journal of Clinical Oncology 30:10, pages 1064-1071.
Crossref
Crossref
Liana Scialdone. (2012) Overview of Supportive Care in Patients Receiving Chemotherapy. Journal of Pharmacy Practice 25:2, pages 209-221.
Crossref
Crossref
Juan José Alonso, Araceli Cánovas, José Guillermo Barreiro & Ciriaco Aguirre. (2012) Infectious complications of chemotherapy in clinically aggressive mature B and T cell lymphomas. European Journal of Internal Medicine 23:3, pages 255-260.
Crossref
Crossref
Ruth Pettengell, Hans E. Johnson, Pieternella J. Lugtenburg, Antonio Salar Silvestre, Ulrich Dührsen, Francesca G. Rossi, Matthias Schwenkglenks, Kate Bendall, Zsolt Szabo & Ulrich Jaeger. (2011) Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Supportive Care in Cancer 20:3, pages 647-652.
Crossref
Crossref
R Pettengell, M Schwenkglenks, P Bacon, S Lawrinson & U Duehrsen. (2011) Pegfilgrastim primary prophylaxis in patients with non‐Hodgkin lymphoma: results from an integrated analysis. Hematological Oncology 29:4, pages 177-184.
Crossref
Crossref
Scott E Evans, Michael J Tuvim, Cory J Fox, Nidhi Sachdev, Leonid Gibiansky & Burton F Dickey. (2011) Inhaled innate immune ligands to prevent pneumonia. British Journal of Pharmacology 163:1, pages 195-206.
Crossref
Crossref
Gary H. Lyman, Nicole M. Kuderer, Jeffrey Crawford, Debra A. Wolff, Eva Culakova, Marek S. Poniewierski & David C. Dale. (2010) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:9, pages 1917-1927.
Crossref
Crossref
Wylie Hosmer, Jennifer Malin & Mitchell Wong. (2010) Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Supportive Care in Cancer 19:3, pages 333-341.
Crossref
Crossref
Gary H Lyman. (2011) A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia. Current Opinion in Hematology 18:1, pages 1-10.
Crossref
Crossref
M.S. Aapro, J. Bohlius, D.A. Cameron, Lissandra Dal Lago, J. Peter Donnelly, N. Kearney, G.H. Lyman, R. Pettengell, V.C. Tjan-Heijnen, J. Walewski, Damien C. Weber & C. Zielinski. (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer 47:1, pages 8-32.
Crossref
Crossref
Laetitia Gerlier, Mark Lamotte, Ahmad Awada, André Bosly, Greet Bries, Véronique Cocquyt, Christian Focan, Stéphanie Henry, Yassine Lalami, Jean-Pascal Machiels, Jeroen Mebis, Nicole Straetmans, Didier Verhoeven & Luc Somers. (2010) The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma. BMC Cancer 10:1.
Crossref
Crossref
Gary H. Lyman, Shannon L. Michels, Matthew W. Reynolds, Rich Barron, Karen Smoyer Tomic & Jingbo Yu. (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116:23, pages 5555-5563.
Crossref
Crossref
Trine Lembrecht Jørgensen, Jesper Hallas, Lotte Holm Land & Jørn Herrstedt. (2010) Comorbidity and polypharmacy in elderly cancer patients: The significance on treatment outcome and tolerance. Journal of Geriatric Oncology 1:2, pages 87-102.
Crossref
Crossref
Gary H. Lyman & Nicole M. Kuderer. 2011. Practical Geriatric Oncology. Practical Geriatric Oncology
323
337
.
Howard A. BurrisIIIIII, Chandra P. Belani, Peter A. Kaufman, Alan N. Gordon, Lee S. Schwartzberg, Warren S. Paroly, Seta Shahin, Lyndah Dreiling & Alan Saven. (2010) Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non–Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. Journal of Oncology Practice 6:3, pages 133-140.
Crossref
Crossref
Gary H. Lyman & Kenneth V. I. Rolston. (2010) How We Treat Febrile Neutropenia in Patients Receiving Cancer Chemotherapy. Journal of Oncology Practice 6:3, pages 149-152.
Crossref
Crossref
Irene Q. Flores & William Ershler. (2010) Managing Neutropenia in Older Patients With Cancer Receiving Chemotherapy in a Community Setting. Clinical Journal of Oncology Nursing 14:1, pages 81-86.
Crossref
Crossref
Gary H. Lyman & Jessica Malone Kleiner. 2011. Hematopoietic Growth Factors in Oncology. Hematopoietic Growth Factors in Oncology
145
165
.
Gary H. Lyman. 2011. Hematopoietic Growth Factors in Oncology. Hematopoietic Growth Factors in Oncology
109
125
.
Michelle Shayne & Lodovico Balducci. 2011. Hematopoietic Growth Factors in Oncology. Hematopoietic Growth Factors in Oncology
383
402
.
John R. Wingard & Mohamed Elmongy. (2009) Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics. Critical Reviews in Oncology/Hematology 72:2, pages 144-154.
Crossref
Crossref
Ruth Pettengell, Matti Aapro, Ercole Brusamolino, Dolores Caballero, Bertrand Coiffier, Michael Pfreundschuh, Marek Trneny & Jan Walewski. (2009) Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) Guidelines on the Use of Granulocyte Colony-Stimulating Factor (G-CSF) for Lymphoma Care. Clinical Drug Investigation 29:8, pages 491-513.
Crossref
Crossref
Jean Klastersky, Ahmad Awada, Michel Aoun & Marianne Paesmans. (2009) Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?. Current Opinion in Oncology 21:4, pages 297-302.
Crossref
Crossref
Ruth Pettengell, André Bosly, Thomas D. Szucs, Christian Jackisch, Robert Leonard, Robert Paridaens, Manuel Constenla & Matthias Schwenkglenks. (2009) Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. British Journal of Haematology 144:5, pages 677-685.
Crossref
Crossref
M. Moreau, J. Klastersky, A. Schwarzbold, F. Muanza, A. Georgala, M. Aoun, A. Loizidou, M. Barette, S. Costantini, M. Delmelle, L. Dubreucq, M. Vekemans, A. Ferrant, D. Bron & M. Paesmans. (2009) A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Annals of Oncology 20:3, pages 513-519.
Crossref
Crossref
E. J. Bow. 2010. Managing Infections in Patients With Hematological Malignancies. Managing Infections in Patients With Hematological Malignancies
259
308
.
Ruth Pettengell, Matthias Schwenkglenks, Robert Leonard, André Bosly, Robert Paridaens, Manuel Constenla, Thomas D. Szucs & Christian Jackisch. (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Supportive Care in Cancer 16:11, pages 1299-1309.
Crossref
Crossref
Haitham W Tuffaha, Imad M TreishLuna Zaru. (2008) The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting. Journal of Oncology Pharmacy Practice 14:3, pages 131-138.
Crossref
Crossref
S. HASHINO, M. MORIOKA, T. IRIE, N. SHIROSHITA, T. KAWAMURA, S. SUZUKI, H. IWASAKI, S. UMEHARA, Y. KAKINOKI, M. KUROSAWA, K. KAHATA, K. IZUMIYAMA, H. KOBAYASHI, M. ONOZAWA, M. TAKAHATA, F. FUJISAWA, T. KONDO & M. ASAKA. (2008) Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma. International Journal of Laboratory Hematology 30:4, pages 292-299.
Crossref
Crossref
Lew M. IacovelliBrandy L. Persson. (2008) Management of Chemotherapy-Induced Neutropenia: Opportunities for Pharmacist Involvement. Hospital Pharmacy 43:6, pages 472-484.
Crossref
Crossref
David C Dale, Jeffrey H Crawford & Gary Lyman. 2008. Cancer Supportive Care: Advances in Therapeutic Strategies. Cancer Supportive Care: Advances in Therapeutic Strategies
1
19
.
Rodrigo O. Perez, Angelita Habr-Gama, Rafael Miyashiro Nunes dos Santos, Igor Proscurshim, Fábio G. Campos, Viviane Rawet, Desiderio Kiss & Ivan Cecconello. (2007) Peritumoral Inflammatory Infiltrate is not a Prognostic Factor in Distal Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. Journal of Gastrointestinal Surgery 11:11, pages 1534-1540.
Crossref
Crossref
G. Romieu, M. Clemens, R. Mahlberg, P. Fargeot, M. Constenla, M. Schütte, V. Easton, T. Skacel, P. Bacon & W. Brugger. (2007) Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial. Critical Reviews in Oncology/Hematology 64:1, pages 64-72.
Crossref
Crossref
Gary H Lyman & Michelle Shayne. (2007) Granulocyte colony-stimulating factors: finding the right indication. Current Opinion in Oncology 19:4, pages 299-307.
Crossref
Crossref
Howard Ozer, Barry Mirtsching, Michael Rader, Susan Luedke, Stephen J. Noga, Beiying Ding & Lyndah Dreiling. (2007) Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use. The Oncologist 12:4, pages 484-494.
Crossref
Crossref
Barbara J. Wilson & Allison E. Gardner. (2007) Nurses' Guide to Understanding and Implementing the National Comprehensive Cancer Network Guidelines for Myeloid Growth Factors. Oncology Nursing Forum 34:2, pages 347-353.
Crossref
Crossref
M.S. Aapro, D.A. Cameron, R. Pettengell, J. Bohlius, J. Crawford, M. Ellis, N. Kearney, G.H. Lyman, V.C. Tjan-Heijnen, J. Walewski, D.C. Weber & C. Zielinski. (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 42:15, pages 2433-2453.
Crossref
Crossref
R. Pirker, E. Ulsperger, J. Messner, K. Aigner, B. Forstner, P. Bacon, V. Easton & T. Skacel. (2006) Achieving Full-Dose, On-Schedule Administration of ACE Chemotherapy Every 14 Days for the Treatment of Patients with Extensive Small-Cell Lung Cancer. Lung 184:5, pages 279-285.
Crossref
Crossref
Johanna N.H. Timmer-Bonte & Vivianne C.G. Tjan-Heijnen. (2006) Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors. Anti-Cancer Drugs 17:8, pages 881-889.
Crossref
Crossref
Kelley Moore & Debbie Crom. (2006) Hematopoietic Support With Moderately Myelosuppressive Chemotherapy Regimens: A Nursing Perspective. Clinical Journal of Oncology Nursing 10:3, pages 383-388.
Crossref
Crossref
Shari Chen-Hardee, Elizabeth A. Chrischilles, Margaret D. Voelker, John M. Brooks, Shane Scott, Brian K. Link & David Delgado. (2006) Population-based Assessment of Hospitalizations for Neutropenia from Chemotherapy in Older Adults with Non-Hodgkin’s Lymphoma (United States). Cancer Causes & Control 17:5, pages 647-654.
Crossref
Crossref
Nicole M. Kuderer, David C. Dale, Jeffrey Crawford, Leon E. Cosler & Gary H. Lyman. (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:10, pages 2258-2266.
Crossref
Crossref
Lowell Anderson-Reitz. (2006) Dose-dense Chemotherapy for Aggressive Non-Hodgkin Lymphoma. Cancer Nursing 29:3, pages 198-206.
Crossref
Crossref
Robert T. Adamson, Indu Lew, A. Scott Mathis & Elena Beyzarov. (2017) Use of Filgrastim among Febrile Inpatients who Received Outpatient Filgrastim or Pegfilgrastim. Hospital Pharmacy 41:3, pages 260-264.
Crossref
Crossref
Gary H. Lyman. (2006) Risks and Consequences of Chemotherapy-Induced Neutropenia. Clinical Cornerstone 8, pages S12-S18.
Crossref
Crossref
Jeffrey Crawford, John A. Glaspy, Ronald G. Stoller, Dianne K. Tomita, Martha E. Vincent, Brian W. McGuire & Howard Ozer. (2005) Final Results of a Placebo-Controlled Study of Filgrastim in Small-Cell Lung Cancer: Exploration of Risk Factors for Febrile Neutropenia. Supportive Cancer Therapy 3:1, pages 36-46.
Crossref
Crossref
Jeffrey Crawford, Michael Green, Brian McGuire & Seta Shahin. (2005) A Combined Analysis of Average Relative Dose Intensity in the Chemotherapy of Solid Tumors with Pegfilgrastim or Filgrastim Support. Supportive Cancer Therapy 2:4, pages 229-233.
Crossref
Crossref
Gary H. Lyman, Christopher H. Lyman & Olayemi Agboola. (2005) Risk Models for Predicting Chemotherapy-Induced Neutropenia. The Oncologist 10:6, pages 427-437.
Crossref
Crossref
Vincent Caggiano, Richard V. Weiss, Timothy S. Rickert & Walter T. Linde-Zwirble. (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:9, pages 1916-1924.
Crossref
Crossref
Charles L. Vogel, Marek Z. Wojtukiewicz, Robert R. Carroll, Sergei A. Tjulandin, Luis Javier Barajas-Figueroa, Brian L. Wiens, Theresa A. Neumann & Lee S. Schwartzberg. (2005) First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study. Journal of Clinical Oncology 23:6, pages 1178-1184.
Crossref
Crossref
Mary E. Ropka, Geraldine Padilla & Theresa W. Gillespie. (2005) Risk Modeling: Applying Evidence-Based Risk Assessment in Oncology Nursing Practice. Oncology Nursing Forum 32:1, pages 49-56.
Crossref
Crossref
E.J. Bow. (2005) Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clinical Microbiology and Infection 11, pages 24-29.
Crossref
Crossref
Nancy White, Cathy Maxwell, Jennifer Michelson & Cindi Bedell. (2005) Protocols for Managing Chemotherapy-induced Neutropenia in Clinical Oncology Practices. Cancer Nursing 28:1, pages 62-69.
Crossref
Crossref
Gary H. Lyman & Nicole M. Kuderer. (2005) Moving Beyond Febrile Neutropenia. Supportive Cancer Therapy 2:2, pages 95-97.
Crossref
Crossref
G. Kesava Reddy, Vinay K. Jain & Jeffrey Crawford. (2005) Highlights from: The 46th Annual Meeting of the American Society of Hematology; San Diego, CA, December 2004. Supportive Cancer Therapy 2:2, pages 79-83.
Crossref
Crossref
Gary H. Lyman, David C. Dale, Jonathan Friedberg, Jeffrey Crawford & Richard I. Fisher. (2004) Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study. Journal of Clinical Oncology 22:21, pages 4302-4311.
Crossref
Crossref
G.H. Lyman & N.M. Kuderer. (2004) The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Critical Reviews in Oncology/Hematology 50:2, pages 129-146.
Crossref
Crossref
Gary H. Lyman & Nicole M. Kuderer. 2004. Hematopoietic Growth Factors in Oncology. Hematopoietic Growth Factors in Oncology
409
443
.
Gary H. Lyman & David J. Delgado. (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP‐R, or CNOP chemotherapy for intermediate‐grade non‐Hodgkin lymphoma. Cancer 98:11, pages 2402-2409.
Crossref
Crossref
Gary H. Lyman, Nicole Kuderer, Olayemi Agboola & Lodovico Balducci. (2017) Evidence-Based Use of Colony-Stimulating Factors in Elderly Cancer Patients. Cancer Control 10:6, pages 487-499.
Crossref
Crossref
R. Paridaens, G.H. Lyman, R. Leonard, J. Crawford, A. Bosly, M. Constenla, C. Jackisch, R. Pettengell & T. Szucs. (2003) Delivering optimal adjuvant chemotherapy in primary breast cancer: the role of rHuG-CSF. European Journal of Cancer Supplements 1:9, pages 1-12.
Crossref
Crossref
Gary H. Lyman & Nicole M. Kuderer. (2003) Epidemiology of Febrile Neutropenia. Supportive Cancer Therapy 1:1, pages 23-35.
Crossref
Crossref